Liquid-phase concentrated growth factor versus arthrocentesis for temporomandibular disc displacement
Injection of Liquid Phase Concentrated Growth Factor Versus Conventional Arthrocentesis in Management of Temporomandibular Disc Displacement: A Randomized Controlled Clinical Trial
This trial will test whether injecting liquid-phase concentrated growth factor into the temporomandibular joint works better than standard arthrocentesis for adults (18–45) with unilateral disc displacement.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 32 (estimated) |
| Ages | 18 Years to 45 Years |
| Sex | All |
| Sponsor | Horus University Academic / other |
| Locations | 1 site (Damietta, New Damietta) |
| Trial ID | NCT07075276 on ClinicalTrials.gov |
What this trial studies
This randomized clinical trial compares liquid-phase concentrated growth factor (LPCGF) injections with conventional arthrocentesis in adults aged 18–45 diagnosed with unilateral temporomandibular disc displacement. Eligible participants are ASA I with near-complete natural dentition and Angle Class I occlusion, and will be randomized to receive either LPCGF or standard arthrocentesis with standardized follow-up visits. Outcomes include pain, joint sounds, maximum mouth opening, and safety measures to determine whether LPCGF provides superior symptom relief or functional improvement. The study is conducted at the Faculty of Dentistry, Horus University in Damietta/New Damietta, Egypt, and excludes patients with prior TMJ surgery or systemic conditions that impair healing.
Who should consider this trial
Good fit: Adults 18–45 years old with unilateral TMJ disc displacement (per RDC/TMD), ASA I status, near-complete natural dentition with Angle Class I occlusion, no prior TMJ surgery, and symptoms such as pain, joint sounds, or limited mouth opening.
Not a fit: Patients with mechanical TMJ deformities, uncontrolled systemic or autoimmune diseases, relevant psychiatric conditions, prior TMJ surgery, or those outside the 18–45 age range are unlikely to qualify or benefit from this intervention.
Why it matters
Potential benefit: If successful, LPCGF could provide better or longer-lasting pain relief and improved jaw opening compared with conventional arthrocentesis.
How similar studies have performed: Other autologous growth-factor therapies (for example PRP or other concentrated growth factors) have shown promising but mixed results in TMJ disorders, so LPCGF represents a relatively novel but plausible approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1\. Adults aged 18-45 years. 2. Patients scored as (ASA I).9 3. Presence of complete or nearly complete set of natural dentition with Angle class I occlusion. 4. Diagnosed with unilateral involvement of disc displacement, according to the Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD).10 5. Symptoms include one or more of the following: pain, joint sounds, and limited mandibular movement (Maximum Mouth Opening\< 40mm) 6. No prior surgical intervention for TMD. 7. Patient's willingness to participate and follow the study protocol. Exclusion Criteria: * 1\. TMJ pathology related to mechanical deformities 2. Psychiatric problems or presence of systemic diseases that may affect healing (e.g., uncontrolled diabetes, autoimmune disorders, hematologic or neurologic disorders, inflammatory or connective tissue disorders as well as rheumatological or previous infectious diseases, head and neck cancer). 3. Patient unwilling or has contraindication to MRI 4. Previous injections or surgical interventions of the TMJ. 5. Concurrent use of anticoagulants or anti-inflammatory medications within the last 30 days. 6. Pregnant or breastfeeding women. 7. History of trauma or infection in the TMJ region. 8. Allergy to local anesthetics or other components used in the study. 9. Patients diagnosed with (Disc Displacement with reduction with no pain or limited mandibular movements).
Where this trial is running
Damietta, New Damietta
- Faculty of Dentistry- Horus University in Egypt — Damietta, New Damietta, Egypt (Recruiting)
Study contacts
- Principal investigator: Mohamed Ali Habib, Teaching Assistant — Horus University in Egypt - Faculty of dentistry
- Study coordinator: Mohamed Ali Habib, Teaching assistant
- Email: mbasiouny@horus.edu.eg
- Phone: +2001069505336
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.